pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

Trump announces steep tariffs on imported generic drugs, starting 100% in 2028 and rising to 200% in 2029

Jul 22, 2026·read at STAT ↗RegulatoryNegative

President Donald Trump disclosed a plan to levy heavy tariffs on generic medicines that are imported into the United States. The tariff would be set at 100 percent beginning in August 2028 and would double to 200 percent in August 2029.

The administration says the measure is intended to encourage pharmaceutical manufacturing to return to U.S. facilities and reduce reliance on foreign sources.

Industry observers note that the proposal could disrupt supply chains for low-cost generics, particularly affecting manufacturers in India that export large volumes to the American market.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more”

read at STAT ↗
679 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GILEAD2LILLY2NOVO2ELI LILLY CONovo Nordisk Inc
topics
GLP-1 receptorHypertension

related stories

  • 1d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Sep 28STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’STAT
  • Sep 14Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandBioSpace
  • Aug 12Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightBioSpace
  • Jul 28Eli Lilly tops new biopharma ranking on launch success, development speedFierce Biotech